Toward optimizing the indications for orthotopic liver transplantation in hepatocellular carcinoma

Didier Samuel, Massimo Colombo, Hachem El-Serag, Rodolphe Sobesky, Nigel Heaton

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Key Points 1. Liver transplantation is currently an effective therapy for patients with HCC who meet the Milan criteria. 2. The proportion of patients on waiting lists for liver transplantation who have HCC has increased substantially in recent years. HCC is currently one of the major indications for liver transplantation; it is the indication for approximately one-third of liver transplants. 3. If the Milan criteria are not met, the survival rates after liver transplantation for HCC tend to decrease, mainly because of the catastrophic consequences of HCC recurrence. 4. A few studies have supported liver transplantation when the Milan criteria are exceeded, but extensions beyond the Milan criteria remain controversial. Even if an individual patient with HCC who does not meet the Milan criteria might benefit from liver transplantation, the limited number of currently available donor organs limits the indications for liver transplantation to those patients with HCC who have the greatest likelihood of survival after the procedure. 5. To patients with early-stage HCC, surgical resection can be offered if the hepatocellular function is well maintained and severe portal hypertension is not present. 6. To enable patients with HCC to have access to liver transplantation that is similar to the access for other patients without HCC in the MELD allocation system, additional points based on the number and size of HCC lesions are assigned to patients on the waiting list. However, this system requires further refinement to ensure that it is as fair as possible. 7. Liver transplantation for HCC should be restricted to those patients who are expected to have the same posttransplant survival as that of patients with nonneoplastic end-stage chronic liver disease. 8. On the basis of these considerations, a 5-year survival rate of 50% after liver transplantation for HCC seems too low.

Original languageEnglish
JournalLiver Transplantation
Volume17
Issue numberSUPPL. 2
DOIs
Publication statusPublished - Oct 2011

Fingerprint

Liver Transplantation
Hepatocellular Carcinoma
Waiting Lists
Survival Rate
End Stage Liver Disease
Survival
Portal Hypertension
Chronic Disease
Tissue Donors
Transplants
Recurrence
Liver

ASJC Scopus subject areas

  • Surgery
  • Transplantation
  • Hepatology

Cite this

Toward optimizing the indications for orthotopic liver transplantation in hepatocellular carcinoma. / Samuel, Didier; Colombo, Massimo; El-Serag, Hachem; Sobesky, Rodolphe; Heaton, Nigel.

In: Liver Transplantation, Vol. 17, No. SUPPL. 2, 10.2011.

Research output: Contribution to journalArticle

Samuel, Didier ; Colombo, Massimo ; El-Serag, Hachem ; Sobesky, Rodolphe ; Heaton, Nigel. / Toward optimizing the indications for orthotopic liver transplantation in hepatocellular carcinoma. In: Liver Transplantation. 2011 ; Vol. 17, No. SUPPL. 2.
@article{e862a78551754340a1aff54a6ffdf875,
title = "Toward optimizing the indications for orthotopic liver transplantation in hepatocellular carcinoma",
abstract = "Key Points 1. Liver transplantation is currently an effective therapy for patients with HCC who meet the Milan criteria. 2. The proportion of patients on waiting lists for liver transplantation who have HCC has increased substantially in recent years. HCC is currently one of the major indications for liver transplantation; it is the indication for approximately one-third of liver transplants. 3. If the Milan criteria are not met, the survival rates after liver transplantation for HCC tend to decrease, mainly because of the catastrophic consequences of HCC recurrence. 4. A few studies have supported liver transplantation when the Milan criteria are exceeded, but extensions beyond the Milan criteria remain controversial. Even if an individual patient with HCC who does not meet the Milan criteria might benefit from liver transplantation, the limited number of currently available donor organs limits the indications for liver transplantation to those patients with HCC who have the greatest likelihood of survival after the procedure. 5. To patients with early-stage HCC, surgical resection can be offered if the hepatocellular function is well maintained and severe portal hypertension is not present. 6. To enable patients with HCC to have access to liver transplantation that is similar to the access for other patients without HCC in the MELD allocation system, additional points based on the number and size of HCC lesions are assigned to patients on the waiting list. However, this system requires further refinement to ensure that it is as fair as possible. 7. Liver transplantation for HCC should be restricted to those patients who are expected to have the same posttransplant survival as that of patients with nonneoplastic end-stage chronic liver disease. 8. On the basis of these considerations, a 5-year survival rate of 50{\%} after liver transplantation for HCC seems too low.",
author = "Didier Samuel and Massimo Colombo and Hachem El-Serag and Rodolphe Sobesky and Nigel Heaton",
year = "2011",
month = "10",
doi = "10.1002/lt.22423",
language = "English",
volume = "17",
journal = "Liver Transplantation",
issn = "1527-6465",
publisher = "John Wiley and Sons Ltd",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Toward optimizing the indications for orthotopic liver transplantation in hepatocellular carcinoma

AU - Samuel, Didier

AU - Colombo, Massimo

AU - El-Serag, Hachem

AU - Sobesky, Rodolphe

AU - Heaton, Nigel

PY - 2011/10

Y1 - 2011/10

N2 - Key Points 1. Liver transplantation is currently an effective therapy for patients with HCC who meet the Milan criteria. 2. The proportion of patients on waiting lists for liver transplantation who have HCC has increased substantially in recent years. HCC is currently one of the major indications for liver transplantation; it is the indication for approximately one-third of liver transplants. 3. If the Milan criteria are not met, the survival rates after liver transplantation for HCC tend to decrease, mainly because of the catastrophic consequences of HCC recurrence. 4. A few studies have supported liver transplantation when the Milan criteria are exceeded, but extensions beyond the Milan criteria remain controversial. Even if an individual patient with HCC who does not meet the Milan criteria might benefit from liver transplantation, the limited number of currently available donor organs limits the indications for liver transplantation to those patients with HCC who have the greatest likelihood of survival after the procedure. 5. To patients with early-stage HCC, surgical resection can be offered if the hepatocellular function is well maintained and severe portal hypertension is not present. 6. To enable patients with HCC to have access to liver transplantation that is similar to the access for other patients without HCC in the MELD allocation system, additional points based on the number and size of HCC lesions are assigned to patients on the waiting list. However, this system requires further refinement to ensure that it is as fair as possible. 7. Liver transplantation for HCC should be restricted to those patients who are expected to have the same posttransplant survival as that of patients with nonneoplastic end-stage chronic liver disease. 8. On the basis of these considerations, a 5-year survival rate of 50% after liver transplantation for HCC seems too low.

AB - Key Points 1. Liver transplantation is currently an effective therapy for patients with HCC who meet the Milan criteria. 2. The proportion of patients on waiting lists for liver transplantation who have HCC has increased substantially in recent years. HCC is currently one of the major indications for liver transplantation; it is the indication for approximately one-third of liver transplants. 3. If the Milan criteria are not met, the survival rates after liver transplantation for HCC tend to decrease, mainly because of the catastrophic consequences of HCC recurrence. 4. A few studies have supported liver transplantation when the Milan criteria are exceeded, but extensions beyond the Milan criteria remain controversial. Even if an individual patient with HCC who does not meet the Milan criteria might benefit from liver transplantation, the limited number of currently available donor organs limits the indications for liver transplantation to those patients with HCC who have the greatest likelihood of survival after the procedure. 5. To patients with early-stage HCC, surgical resection can be offered if the hepatocellular function is well maintained and severe portal hypertension is not present. 6. To enable patients with HCC to have access to liver transplantation that is similar to the access for other patients without HCC in the MELD allocation system, additional points based on the number and size of HCC lesions are assigned to patients on the waiting list. However, this system requires further refinement to ensure that it is as fair as possible. 7. Liver transplantation for HCC should be restricted to those patients who are expected to have the same posttransplant survival as that of patients with nonneoplastic end-stage chronic liver disease. 8. On the basis of these considerations, a 5-year survival rate of 50% after liver transplantation for HCC seems too low.

UR - http://www.scopus.com/inward/record.url?scp=80053250896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053250896&partnerID=8YFLogxK

U2 - 10.1002/lt.22423

DO - 10.1002/lt.22423

M3 - Article

C2 - 21858912

AN - SCOPUS:80053250896

VL - 17

JO - Liver Transplantation

JF - Liver Transplantation

SN - 1527-6465

IS - SUPPL. 2

ER -